Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Thalia Therapeutics Plc

Market Cap 4.37M 5.85M 5.05M 4.64M 8.21M 552M 8.28M 55.01M 21.42M 271M 21.97M 21.5M 938M P/E 2023
-1.63x
P/E 2024 -1.69x
Enterprise Value 3.74M 5.01M 4.33M 3.98M 7.03M 473M 7.09M 47.13M 18.35M 232M 18.82M 18.42M 803M EV / Sales 2023
643,891,449x
EV / Sales 2024 198,657,512x
Free-Float
62.16%
Yield 2023 *
-
Yield 2024 -

Last Transcript: Thalia Therapeutics Plc

Current month-11.54%
1 month-14.81%
3 months+21.05%
6 months+9.52%
Current year+9.52%
1 week 0.55
Extreme 0.55
0.6
1 month 0.55
Extreme 0.55
0.75
Current year 0.4
Extreme 0.4
0.95
1 year 0.35
Extreme 0.35
1
3 years 0.35
Extreme 0.35
2.1
5 years 0.35
Extreme 0.35
10.43
10 years 0.35
Extreme 0.35
35.7
Manager TitleAgeSince
Chief Executive Officer 65 24/02/2026
Chief Tech/Sci/R&D Officer 56 27/05/2025
Corporate Officer/Principal - 27/05/2025
Director TitleAgeSince
Director/Board Member 48 14/07/2020
Chairman - 01/08/2023
Director/Board Member 80 09/09/2024
Date Insider Type Main position Quantity % Market Cap.
28/11/24Free

Chairman

3,000,000 0.7599%
28/11/24Free

Director

3,000,000 0.7599%
28/11/24Free

Founder

6,000,000 1.5198%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%+27.78%-66.18% 6.42M
+3.23%+2.93%+61.50%+113.87% 54.54B
+0.04%+5.05%+43.44%+36.75% 43.86B
+3.04%+7.05%-12.15%-16.12% 22.63B
+3.07%+7.15%-1.82%+387.14% 20.7B
-0.53%-0.27%+12.68%-37.07% 15.84B
+5.27%+1.71%+11.09%-38.81% 14.83B
+0.65%-0.27%+26.80%+176.87% 13.1B
-5.17%+4.13%+13.12% - 12.66B
-0.27%+6.06%+78.78%+103.63% 11.56B
Average +0.93%+0.16%+26.12%+73.34% 20.97B
Weighted average by Cap. +1.53%+0.18%+32.14%+90.45%

Financials

2023 2024
Net sales 0 0 0 0 0 0.25 0 0.02 0.01 0.12 0.01 0.01 0.42 0.01 0.01 0.01 0.01 0.01 0.92 0.01 0.09 0.04 0.45 0.04 0.04 1.56
Net income -1.27M -1.7M -1.47M -1.35M -2.39M -160M -2.41M -15.98M -6.22M -78.75M -6.38M -6.25M -272M -1.06M -1.42M -1.22M -1.12M -1.99M -134M -2.01M -13.33M -5.19M -65.68M -5.32M -5.21M -227M
Net Debt -1.03M -1.38M -1.19M -1.09M -1.93M -130M -1.95M -12.93M -5.03M -63.72M -5.16M -5.05M -220M -626K -838K -723K -665K -1.18M -79.13M -1.19M -7.88M -3.07M -38.84M -3.15M -3.08M -134M
Logo Thalia Therapeutics Plc
Thalia Therapeutics PLC, formerly N4 Pharma plc, is a biotechnology company developing RNA-based therapeutics and delivery technologies in oncology and cardiovascular disease. The Company is developing proprietary RNA delivery technologies (Nuvec) designed to enable multi-RNA loading, flexible targeting and the potential for oral delivery. Nuvec is based on amorphous silica and has an irregular surface structure that simply and effectively traps and protects RNA as it travels to target cells. The Nuvec delivery system can be functionalized by attaching a wide range of proteins, peptides, antibodies or radionuclides for therapeutic purposes. The Company has a growing pipeline of RNA-based programs across oncology and cardiovascular disease, including Dual-target cardiovascular siRNA program and Proprietary RNA delivery technology. The Company is advancing a novel long-duration, dual-acting siRNA program targeting PCSK9 and lipoprotein.
Employees
4
Date Price Change Volume
17/06/26 0.5750 p 0.00% 159,396
16/06/26 0.5750 p 0.00% 17,341
15/06/26 0.5750 p 0.00% 490,951
12/06/26 0.5750 p 0.00% 7,058
11/06/26 0.5750 p 0.00% 172,024
  1. Stock Market
  2. Stocks
  3. THAT Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!